Tom Powles, MIBC

Tom Powles: Bladder cancer highlights at ASCOGU25

Tom Powles, Professor at the University of London and Director of Barts Cancer Centre, shared a post on X:

“Bladder cancer highlights ASCOGU25:

  1. Outcomes of pCR patients for gem/cis/durvalumab (NIAGARA).
  2. Neoadjuvant gem/cis/durvalumab in upper tract disease.
  3. Neoadjuvant DV/PD1 in MIBC (pCR >50%?).
  4. Longer OS follow up for EVP 4) Data on DDXD and new FGFR3i in pretreated patients.”
ASCOGU25 Barts Cancer Centre bladder cancer cancer Durvalumab fight against cancer Global fight against cancer OncoDaily Oncology Tom Powles University of London